RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Public
Established
2002-01-01
Employees
11
Market Cap
-
Website
http://www.regenerx.com
Clinical Trials
Related News

A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction

First Posted Date
2011-03-09
Last Posted Date
2021-09-22
Lead Sponsor
RegeneRx Biopharmaceuticals, Inc.
Registration Number
NCT01311518

Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers

Phase 2
Completed
Conditions
Venous Stasis Ulcers
Interventions
Drug: Placebo
Drug: Thymosin Beta 4
First Posted Date
2009-01-29
Last Posted Date
2010-03-30
Lead Sponsor
RegeneRx Biopharmaceuticals, Inc.
Target Recruit Count
72
Registration Number
NCT00832091
Locations
🇮🇹

Università degli Studi di Napoli - Federico II, Naples, Italy

🇮🇹

Istituto Dermopatico dell'Immacolata (IDI), Rome, Italy

🇵🇱

Klinika Chirurgii Naczyń i Angiologii, Lublin, Poland

and more 5 locations

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

First Posted Date
2008-08-29
Last Posted Date
2017-04-17
Lead Sponsor
RegeneRx Biopharmaceuticals, Inc.
Registration Number
NCT00743769
Locations
🇺🇸

Healthcare Discoveries LLC, San Antonio, Texas, United States

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Phase 2
Completed
Conditions
Pressure Ulcers
Interventions
Drug: Placebo
Drug: Thymosin Beta 4
First Posted Date
2006-09-28
Last Posted Date
2010-02-01
Lead Sponsor
RegeneRx Biopharmaceuticals, Inc.
Target Recruit Count
72
Registration Number
NCT00382174
Locations
🇺🇸

Impact Clinical Trials, Beverly Hills, California, United States

🇺🇸

Hines VAMC, Hines, Illinois, United States

🇺🇸

Institute for Advanced Wound Care, Montgomery, Alabama, United States

and more 9 locations

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Phase 2
Terminated
Conditions
Epidermolysis Bullosa
Interventions
Drug: Placebo
Drug: Thymosin Beta 4
First Posted Date
2006-04-06
Last Posted Date
2014-05-12
Lead Sponsor
RegeneRx Biopharmaceuticals, Inc.
Target Recruit Count
30
Registration Number
NCT00311766
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy